ESC 2020 Archives - Medical Conferences

Letter from the Editor

Editor

Prof. Marc Bonaca, University of Colorado, USA

ESC 2020 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

2020 Atrial Fibrillation Guidelines

Presented By

Prof. Gerhard Hindricks, Heart Centre Leipzig, Germany

2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines

Presented By

Prof. Jean-Phillippe Collet, Pitié-Salpêtrière Hospital, France

2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines

Presented By

Prof. Antonio Pelliccia, Institute of Sports Medicine and Science, Italy

2020 Adult Congenital Heart Disease Guidelines

Presented By

Prof. Helmut Baumgartner, University Hospital Münster, Germany

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

Presented By

Dr Milton Packer, Baylor University Medical Center, USA

First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy

Presented By

Prof. Iacopo Olivotto, Azienda Ospedaliera Universitaria Careggi, Italy

Reduced cardiovascular outcomes with early rhythm control

Presented By

Prof. Paulus Kirchhof, University Heart & Vascular Center Hamburg, Germany

Trimetazidine after successful PCI not associated with fewer cardiac events

Presented By

Prof. Roberto Ferrari, University of Ferrara, Italy

POPular TAVI: Aspirin-only antiplatelet strategy?

Presented By

Dr Jorn Brouwer, St Antonius Hospital, the Netherlands

Reduced NT-proBNP in HFpEF with sacubitril/valsartan

Presented By

Prof. Burkert Pieske, Charité University Medicine Berlin, Germany

DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

Presented By

Prof. Hiddo Heerspink, University of Groningen, the Netherlands

Low-dose colchicine reduces CV death and ischaemic events in coronary disease

Presented By

Dr Stefan Nidorf, Heart Care Western Australia, Australia

Similar outcomes sPESI and HESTIA for pulmonary embolism triage

Presented By

Prof. Pierre-Marie Roy, University Hospital of Angers, France

Antihypertensives also reduce CV risk in people with normal blood pressure

Presented By

Prof. Kazem Rahimi, University of Oxford, UK

COVID-19: Continuing versus suspending ACE inhibitors and ARBs

Presented By

Prof. Renato Lopes, Duke University, USA

Drug initiation strategy not associated with increased use of oral anticoagulants

Presented By

Prof. Sean Pokorney , Duke University, USA

Restrictive blood transfusion non-inferior and cost-effective strategy

Presented By

Prof. Philippe Gabriel Steg, University of Paris, Frane

Increased mortality with colchicine in patients with ACS

Presented By

Prof. Jamie Layland , Monash University, Australia

Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients

Presented By

Prof. William Hiatt, University of Colorado, USA

Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins

Presented By

Prof. Jean-Claude Tardif, University of Montréal, Canada

Antisense ANGPTL3 lowers triglycerides

Presented By

Prof. Daniel Gaudet, University of Montréal, Canada

Reduced progression of coronary atherosclerosis with icosapent ethyl

Presented By

Prof. Matthew Budoff, Harbor-UCLA Medical Center, USA

Digoxin improves symptoms in stable patients with permanent AF

Presented By

Prof. Dipak Kotecha, University of Birmingham, UK

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

Presented By

Prof. Francesco Cosentino, Karolinska University Hospital, Sweden

Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan

Presented By

Prof. Yutao Guo , Chinese PLA General Hospital, China

The Yale COVID-19 Cardiovascular Registry

Presented By

Dr Manan Pareek, Yale University School of Medicine, USA

COVID-19 treatments and the importance of randomised trials

Presented By

Prof. Martin Landray, University of Oxford, UK

Medical Conferences

ESC 2020

Table of Contents

Featured articles

Letter from the Editor

ESC 2020 Highlights Podcast

2020 ESC Clinical Practice Guidelines

2020 Atrial Fibrillation Guidelines

2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines

2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines

2020 Adult Congenital Heart Disease Guidelines

Hot Line Presentations

SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients

First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy

Reduced cardiovascular outcomes with early rhythm control

Trimetazidine after successful PCI not associated with fewer cardiac events

POPular TAVI: Aspirin-only antiplatelet strategy?

Reduced NT-proBNP in HFpEF with sacubitril/valsartan

DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes

Low-dose colchicine reduces CV death and ischaemic events in coronary disease

Similar outcomes sPESI and HESTIA for pulmonary embolism triage

Antihypertensives also reduce CV risk in people with normal blood pressure

COVID-19: Continuing versus suspending ACE inhibitors and ARBs

Drug initiation strategy not associated with increased use of oral anticoagulants

Restrictive blood transfusion non-inferior and cost-effective strategy

Late-Breaking Science

Increased mortality with colchicine in patients with ACS

Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients

Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins

Antisense ANGPTL3 lowers triglycerides

Reduced progression of coronary atherosclerosis with icosapent ethyl

Digoxin improves symptoms in stable patients with permanent AF

SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations

COVID and Cardiovascular Disease

Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan

The Yale COVID-19 Cardiovascular Registry

COVID-19 treatments and the importance of randomised trials